VEGF 

 522 Products   522 Products   1193 Diseases   181847 News 


12345678910111213...19871988»
  • ||||||||||  sorafenib / Generic mfg.
    Journal:  TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway. (Pubmed Central) -  Jun 18, 2025   
    This study underscores STK25 antagonism as a promising therapeutic strategy for the prevention and treatment of HCC in the context of MASH. TGM2 serves as a prognostic biomarker and targeting its transglutaminase activity may be an effective strategy for inhibiting HCC progression.
  • ||||||||||  Inlyta (axitinib) / Pfizer, Sulanda (surufatinib) / Hutchmed, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors. (Pubmed Central) -  Jun 18, 2025   
    Current approaches in managing advanced GEP-NETs are discussed, including somatostatin analogs, surgery, peptide receptor radionuclide therapy, and approved systemic treatments such as everolimus or sunitinib...Discussions focus on the clinical effectiveness and the emerging role of both established and novel MKIs in the treatment of GEP-NETs, including recent evidence from the CABINET trial and other emerging agents such as surufatinib, axitinib, pazopanib, and lenvatinib...There remain several unmet needs that must be addressed, particularly regarding optimal treatment sequencing and the development of predictive biomarkers. Ongoing research and the use of current and emerging MKIs hold great potential to advance the treatment landscape for advanced GEP-NETs significantly.
  • ||||||||||  Iclusig (ponatinib) / Takeda
    Journal:  Ponatinib-related gelatinous transformation of the bone marrow. (Pubmed Central) -  Jun 18, 2025   
    Ongoing research and the use of current and emerging MKIs hold great potential to advance the treatment landscape for advanced GEP-NETs significantly. No abstract available
  • ||||||||||  treprostinil / Generic mfg., nintedanib / Generic mfg., pirfenidone / Generic mfg.
    Review, Journal:  A new era in the treatment of progressive fibrosing interstitial lung diseases. (Pubmed Central) -  Jun 18, 2025   
    This includes phosphodiesterase 4 inhibitors, ?v?6 and ?v?1 integrin inhibitors, lymphosphatidic acid antagonists, inhaled treprostinil, hedgehog inhibitors, tyrosine kinase inhibitors and angiotensin type 2 receptor agonists. The aim is also to better understand current therapeutic challenges and future perspectives, including cellular therapies, exosomes and their cargoes, as well as the integration of transcriptomics and proteomics, plus gene therapy.
  • ||||||||||  Vabysmo (faricimab-svoa) / Roche
    Journal, Real-world evidence:  Faricimab Outcomes in Chorioretinal Disorders: Indian Real-World Analysis (FOCUS Study). (Pubmed Central) -  Jun 18, 2025   
    Faricimab demonstrated significant visual and anatomical improvements across all diagnostic groups, including off?label use in RVO?associated CME during the study period, showing promise as an effective treatment for DME, nAMD, and RVO. These real-world outcomes align with clinical trial data (TENAYA, LUCERNE, YOSEMITE, RHINE), underscoring faricimab's potential as an effective, dual-action therapy for chorioretinal disorders.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Biomarker, Journal:  Prognostic factors of conbercept intravitreal injection in the treatment of choroidal neovascularization secondary to pathologic myopia. (Pubmed Central) -  Jun 18, 2025   
    The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR)?=?1.303, 95% confidence interval (CI): 1.059-1.603, P?=?0.012), baseline BCVA (OR?=?15.939, 95% CI: 2.490-102.013, P?=?0.003), subfoveal CNV (OR?=?0.055, 95% CI: 0.010-0.312, P?=?0.001), and well-organized CNV (OR?=?0.049, 95% CI: 0.009-0.276, P?=?0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV.
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, arcotatug tavatecan (IBI-343) / Innovent Biologics
    New P1/2 trial:  IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer (clinicaltrials.gov) -  Jun 18, 2025   
    P1/2,  N=55, Recruiting, 
  • ||||||||||  cyclophosphamide / Generic mfg., nintedanib / Generic mfg., pirfenidone / Generic mfg.
    Clinical, Review, Journal:  Clinical trials on acute exacerbations of interstitial lung diseases. (Pubmed Central) -  Jun 17, 2025   
    Shifting clinical practice away from harmful therapies toward precision medicine approaches, utilizing biomarkers, preventive antifibrotic strategies, and novel therapeutic targets, is essential. International collaboration in clinical research is crucial to improve patient outcomes.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  An endothelial cell competition assay for determinants of the response to targeted anti-angiogenics. (Pubmed Central) -  Jun 17, 2025   
    A normalized ratio of surviving cells, obtained by flow cytometry analysis, reflects EC resistance or sensitization to bevacizumab mediated by the experimental shRNA. With reagents prepared, the protocol takes 10?days and rigorously quantifies the impact of gene perturbation on the EC response to bevacizumab or other targeted anti-angiogenics.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Retrospective data, Journal:  Treatments and Outcomes After Platinum-Based Chemotherapy and Anti-PD-(L)1 in NSCLC. (Pubmed Central) -  Jun 17, 2025   
    In exploratory analyses, these outcomes were numerically shorter in patients who received chemotherapy monotherapy as index treatment vs the overall group; medians were numerically longer in patients who received index treatments of immuno-oncology monotherapy or chemotherapy plus immuno-oncology combination therapy. In this retrospective cohort study of patients with advanced or metastatic NSCLC, results underscored a significant need for novel treatments, including immuno-oncology combinations.
  • ||||||||||  Biomarker, Journal:  Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment. (Pubmed Central) -  Jun 17, 2025   
    We present a 62-year-old male with mCRC harboring BRAF, MET, APC, TP53 and NRAS alterations, following FOLFOX and FOLFIRI, dabrafenib plus panitumumab, and a BRAF inhibitor clinical trial, each leading to initial responses followed by disease progression...Personalized combinations suggested included amivantamab-vmjw (anti-MET/EGFR antibody) (one-third standard dose) (for MET amplification and due to prior response to anti-EGFR antibody), trametinib, 1 mg po daily (MEK inhibitor for BRAF V600E mutation), and regorafenib (may have WNT inhibitor activity relevant to APC mutation; VEGFR activity relevant since TP53 alterations upregulate VEGF/VEGFR axis) starting at 40 mg po daily three weeks on, one week off. Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m
  • ||||||||||  Yesafili (aflibercept-jbvf) / J&J, Biocon, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Clinical Trials of Aflibercept Biosimilars: A Review. (Pubmed Central) -  Jun 17, 2025   
    Understanding the study designs of biosimilars can mitigate negative perceptions of biosimilars and promote their active implementation. In this review, we provide a comprehensive comparison of the designs of phase III clinical trials of aflibercept biosimilars, including recently published results.
  • ||||||||||  Signifor (pasireotide) / Recordati
    Journal:  Efficacy and safety of Pasireotide in Insulinoma-associated hypoglycemia: a Systematic Review. (Pubmed Central) -  Jun 17, 2025   
    However, its efficacy was lower in aggressive insulinomas, emphasizing the need for alternative or combinatory strategies in metastatic cases. Given that pasireotide was never used as a first-line therapy in the reviewed cases, earlier administration in selected patients may improve outcomes.
  • ||||||||||  everolimus / Generic mfg., amiloride hydrochloride / Generic mfg.
    Journal:  Dual Diagnostic Dilemma: Gitelman Syndrome and Incidental Neuroendocrine Tumor in a Young Adult With Refractory Hypokalemia. (Pubmed Central) -  Jun 17, 2025   
    Moreover, it emphasizes the limitations in managing double disease entities in a young individual and the insurmountable hurdles for?advanced treatments like peptide receptor radionuclide therapy in underdeveloped nations. This report highlights the importance of further studying the association between the interplay of genetic syndromes (such as Gitelman syndrome) and associated neoplasms, as well as the vital coordination of complex and multidisciplinary management in rare clinical situations.
  • ||||||||||  limantrafin (CB-103) / Cellestia Biotech, Lenvima (lenvatinib) / Eisai, Merck (MSD), Verzenio (abemaciclib) / Eli Lilly
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date:  CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC (clinicaltrials.gov) -  Jun 17, 2025   
    P1/2,  N=32, Recruiting, 
    This report highlights the importance of further studying the association between the interplay of genetic syndromes (such as Gitelman syndrome) and associated neoplasms, as well as the vital coordination of complex and multidisciplinary management in rare clinical situations. N=10 --> 32 | Active, not recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2026
  • ||||||||||  PEGylated camptothecin (PEEL-224) / PEEL Therap
    Enrollment change, Trial primary completion date:  PEEL-224-001: A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jun 17, 2025   
    P1,  N=65, Recruiting, 
    N=10 --> 32 | Active, not recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2026 N=42 --> 65 | Trial primary completion date: Mar 2025 --> Dec 2025
  • ||||||||||  Cabometyx (cabozantinib tablet) / Exelixis
    Review, Journal:  Cabozantinib in the Treatment of Neuroendocrine Neoplasms: Insights Across Different Tumor Origins. (Pubmed Central) -  Jun 16, 2025   
    However, cabozantinib's complex toxicity profile limits its broad application, necessitating further research to optimize dosing, particularly in syndromic NENs. Ongoing trials are investigating cabozantinib in combination with somatostatin analogs, peptide receptor radionuclide therapy, temozolomide, and immunotherapies in order to overcome treatment resistance and expanding therapeutic strategies for advanced NENs.
  • ||||||||||  Xospata (gilteritinib) / Astellas
    Trial completion date:  PrE0905: Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 16, 2025   
    P2,  N=181, Active, not recruiting, 
    Potential biological differences between meningiomas and schwannomas that underlie this differential response to bevacizumab warrant further investigation. Trial completion date: Jun 2025 --> Dec 2026
  • ||||||||||  lapatinib / Generic mfg., Inlyta (axitinib) / Pfizer, TAK-285 / Takeda
    Journal:  Identification of novel HER2 ?nhibitors: potential therapeutics for breast cancer. (Pubmed Central) -  Jun 16, 2025   
    Prunetin, with its lower toxicity and higher stability, presents a safer therapeutic option, whereas axitinib offers high binding affinity. These findings suggest that these compounds could help overcome resistance and side effects associated with current HER2-targeted therapies.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Investigating the therapeutic role of anlotinib in radiation-induced lung injury. (Pubmed Central) -  Jun 16, 2025   
    Metformin has some anti-inflammatory and immunoprotective effects on NSCLC patients treated with chemotherapy combined with bevacizumab, which may help to attenuate the vascular endothelial injury induced by chemotherapy and bevacizumab treatment and further improve the prognosis. Therefore,
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Exosome-derived hsa_circ_0007132 promotes lenvatinib resistance by inhibiting the ubiquitin-mediated degradation of NONO. (Pubmed Central) -  Jun 16, 2025   
    Mechanistically, hsa_circ_0007132 interacts with the NONO protein, impairing its ubiquitination and leading to increased stability and upregulation of NONO expression, thereby enhancing NONO-mediated nuclear export of ZEB1 mRNA and elevating ZEB1 protein expression, which ultimately contributes to LR. In summary, our findings unveil a critical mechanism through which HCC mediates tumor progression and LR via exosomal hsa_circ_0007132, while also emphasizing that targeting NONO may represent a promising therapeutic strategy to overcome LR.